Assessment of neuroprotective effects of glutamate modulation on glaucoma-related retinal ganglion cell apoptosis in vivo

Investigative Ophthalmology and Visual Science

Volumn 47, Issue 2, 2006, Pages 626-633

  Guo, Li ^a   Salt, Thomas E ^a   Maass, Annelie ^a   Luong, Vy ^a   Moss, Stephen E ^a   Fitzke, Fred W ^a   Cordeiro, M Francesca ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIZOCILPINE; EGLUMETAD; IFENPRODIL; STAUROSPORINE; AMINO ACID RECEPTOR BLOCKING AGENT; AMINO ACID RECEPTOR STIMULATING AGENT; BICYCLO COMPOUND; DIZOCILPINE MALEATE; GLUTAMIC ACID; METABOTROPIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROPROTECTIVE AGENT; PIPERIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; GLAUCOMA; HISTOLOGY; IMAGING; IN VIVO STUDY; INTRAOCULAR HYPERTENSION; LOW DRUG DOSE; MALE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; RETINA GANGLION CELL; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; DRUG POTENTIATION; INTRAOCULAR PRESSURE; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; APOPTOSIS; BICYCLO COMPOUNDS; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; EXCITATORY AMINO ACID AGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; GLAUCOMA; GLUTAMIC ACID; INTRAOCULAR PRESSURE; MALE; NEUROPROTECTIVE AGENTS; OCULAR HYPERTENSION; PIPERIDINES; RATS; RECEPTORS, METABOTROPIC GLUTAMATE; RECEPTORS, N-METHYL-D-ASPARTATE; RETINAL GANGLION CELLS; STAUROSPORINE;

EID: 33644851946     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.05-0754     Document Type: Article

References (60)

1. Quigley HA, Nickells RW, Kerrigan LA, Pease ME, Thibault DJ, Zack DJ. Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. Invest Ophthalmol Vis Sci. 1995;36:774-786.
2. Guo L, Moss SE, Alexander RA, Ali RR, Fitzke FW, Cordeiro MF. Retinal ganglion cell apoptosis in glaucoma is related to intraocular pressure (IOP) and IOP-induced effects on extracellular matrix. Invest Ophthalmol Vis Sci. 2005;46:175-182.
3. Cordeiro MF, Guo L, Luong V, et al. Real time imaging of single nerve cell apoptosis in retinal neurodegeneration. Proc Natl Acad Sci USA. 2004;101:13352-13356.
4. Osborne NN, Ugarte M, Chao M, et al. Neuroprotection in relation to retinal ischemia and relevance to glaucoma. Surv Ophthalmol. 1999;43:S102-S128.
5. Martin KR, Levkovitch-Verbin H, Valenta D, Baumrind L, Pease ME, Quigley HA. Retinal glutamate transporter changes in experimental glaucoma and after optic nerve transection in the rat. Invest Ophthalmol Vis Sci. 2002;43:2236-2243.
6. Vorwerk CK, Gorla MS, Dreyer EB. An experimental basis for implicating excitotoxicity in glaucomatous optic neuropathy. Surv Ophthalmol. 1999;43:S142-S150.
7. Hollmann M, Heinemann S. Cloned glutamate receptors. Annu Rev Neurosci. 1994;17:31-108.
8. Yang XL. Characterization of receptors for glutamate and GABA in retinal neurons. Prog Neurobiol. 2004;73:127-150.
9. el-Asrar AM, Morse PH, Maimone D, Torczynski E, Reder AT. MK-801 protects retinal neurons from hypoxia and the toxicity of glutamate and aspartate. Invest Ophthalmol Vis Sci. 1992;33:3463-3468.
10. Lam TT, Siew E, Chu R, Tso MO. Ameliorative effect of MK-801 on retinal ischemia. J Ocul Pharmacol Ther. 1997;13:129-137.
11. Calzada JI, Jones BE, Netland PA, Johnson DA. Glutamate-induced excitotoxicity in retina: neuroprotection with receptor antagonist, dextromethorphan, but not with calcium channel blockers. Neurochem Res. 2002;27:79-88.
12. Osborne NN, Cazevieille C, Wood JP, et al. Flupirtine, a nonopioid centrally acting analgesic, acts as an NMDA antagonist. Gen Pharmacol. 1998;30:255-263.
13. Pang IH, Wexler EM, Nawy S, DeSantis L, Kapin MA. Protection by eliprodil against excitotoxicity in cultured rat retinal ganglion cells. Invest Ophthalmol Vis Sci. 1999;40:1170-1176.
14. Fletcher EL, Hack I, Brandstatter JH, Wassle H. Synaptic localization of NMDA receptor subunits in the rat retina. J Comp Neurol. 2000;420:98-112.
15. Kwon YH, Rickman DW, Baruah S, et al. Vitreous and retinal amino acid concentrations in experimental central retinal artery occlusion in the primate. Eye. 2005;19:455-463.
16. Lotery AJ. Glutamate excitotoxicity in glaucoma: truth or fiction? Eye. 2005;19:369-370.
17. Salt TE, Cordeiro MF. Glutamate excitotoxicity in glaucoma: throwing the baby out with the bathwater? (Letter). Eye. 2005;10:10.
18. Levin LA. Retinal ganglion cells and neuroprotection for glaucoma. Surv Ophthalmol. 2003;48:S21-S24.
19. Kaushik S, Pandav SS, Ram J. Neuroprotection in glaucoma. J Postgrad Med. 2003;49:90-95.
20. Schori H, Kipnis J, Yoles E, et al. Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma. Proc Natl Acad Sci USA. 2001;98:3398-403.
21. Levkovitch-Verbin H, Quigley HA, Martin KR, Zack DJ, Pease ME, Valenta DF. A model to study differences between primary and secondary degeneration of retinal ganglion cells in rats by partial optic nerve transection. Invest Ophthalmol Vis Sci. 2003;44:3388-3393.
22. Levkovitch-Verbin H, Quigley HA, Kerrigan-Baumrind LA, D'Anna SA, Kerrigan D, Pease ME. Optic nerve transection in monkeys may result in secondary degeneration of retinal ganglion cells. Invest Ophthalmol Vis Sci. 2001;42:975-982.
23. Osborne NN, Chidlow G, Layton CJ, Wood JP, Casson RJ, Melena J. Optic nerve and neuroprotection strategies. Eye. 2004;18:1075-1084.
24. Chaudhary P, Ahmed F, Sharma SC. MK801: a neuroprotectant in rat hypertensive eyes. Brain Res. 1998;792:154-158.
25. WoldeMussie E, Yoles E, Schwartz M, Ruiz G, Wheeler LA. Neuroprotective effect of memantine in different retinal injury models in rats. J Glaucoma. 2002;11:474-480.
26. Hare WA, WoldeMussie E, Weinreb RN, et al. Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, II: Structural measures. Invest Ophthalmol Vis Sci. 2004;45:2640-2651.
27. Hare WA, WoldeMussie E, Lai RK, et al. Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, I: Functional measures. Invest Ophthalmol Vis Sci. 2004;45:2625-2639.
28. Pin JP, Duvoisin R. The metabotropic glutamate receptors: structure and functions. Neuropharmacology. 1995;34:1-26.
29. Nicoletti F, Bruno V, Copani A, Casabona G, Knopfel T. Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders? Trends Neurosci. 1996;19:267-271.
30. Shen W, Slaughter MM. Metabotropic and ionotropic glutamate receptors regulate calcium channel currents in salamander retinal ganglion cells. J Physiol. 1998;510:815-828.
31. Hartveit E, Brandstatter JH, Enz R, Wassle H. Expression of the mRNA of seven metabotropic glutamate receptors (mGluR1-7) in the rat retina: an in situ hybridization study on tissue sections and isolated cells. Eur J Neurosci. 1995;7:1472-1483.
32. Tehrani A, Wheeler-Schilling TH, Guenther E. Coexpression patterns of mGLuR mRNAs in rat retinal ganglion cells: a single-cell RT-PCR study. Invest Ophthalmol Vis Sci. 2000;41:314-319.
33. Robbins J, Reynolds AM, Treseder S, Davies R. Enhancement of low-voltage-activated calcium currents by group II metabotropic glutamate receptors in rat retinal ganglion cells. Mol Cell Neurosci. 2003;23:341-350.
34. Higgs MH, Lukasiewicz PD. Activation of group II metabotropic glutamate receptors inhibits glutamate release from salamander retinal photoreceptors. Vis Neurosci. 2002;19:275-281.
35. Dyka FM, May CA, Enz R. Metabotropic glutamate receptors are differentially regulated under elevated intraocular pressure. J Neurochem. 2004;90:190-202.
36. Kermer P, Klocker N, Bahr M. Modulation of metabotropic glutamate receptors fails to prevent the loss of adult rat retinal ganglion cells following axotomy or N-methyl-D-aspartate lesion in vivo. Neurosci Lett. 2001;315:117-120.
37. Guo L, Tsatourin V, Luong V, et al. En-face optical coherence tomography (OCT): a new method to analyze structural changes of the optic nerve head in rat glaucoma. Br J Ophthalmol. 2005;89:1210-1216.
38. Morrison JC, Moore CG, Deppmeier LM, Gold BG, Meshul CK, Johnson EC. A rat model of chronic pressure-induced optic nerve damage. Exp Eye Res. 1997;64:85-96.
39. Lipton SA. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders. J Alzheimers Dis. 2004;6:S61-S74.
40. Farlow MR. NMDA receptor antagonists: a new therapeutic approach for Alzheimer's disease. Geriatrics. 2004;59:22-27.
41. Ullian EM, Barkis WB, Chen S, Diamond JS, Barres BA. Invulnerability of retinal ganglion cells to NMDA excitotoxicity. Mol Cell Neurosci. 2004;26:544-557.
42. Lipton SA. Retinal ganglion cells, glaucoma and neuroprotection. Prog Brain Res. 2001;131:712-718.
43. Sun Q, Ooi VE, Chan SO. N-methyl-D-aspartate-induced excitotoxicity in adult rat retina is antagonized by single systemic injection of MK-801. Exp Brain Res. 2001;138:37-45.
44. Lipton SA. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRx. 2004;1:101-110.
45. Williams AJ, Dave JR, Lu XM, Ling G, Tortella FC. Selective NR2B NMDA receptor antagonists are protective against staurosporine-induced apoptosis. Eur J Pharmacol. 2002;452:135-136.
46. Monn JA, Valli MJ, Massey SM, et al. Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6- dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. J Med Chem. 1997;40:528-537.
47. Kingston AE, O'Neill MJ, Lam A, Bales KR, Monn JA, Schoepp DD. Neuroprotection by metabotropic glutamate receptor glutamate receptor agonists: LY354740, LY379268 and LY389795. Eur J Pharmacol. 1999;377:155-165.
48. Bond A, O'Neill MJ, Hicks CA, Monn JA, Lodge D. Neuroprotective effects of a systemically active group II metabotropic glutamate receptor agonist LY354740 in a gerbil model of global ischaemia. Neuroreport. 1998;9:1191-1193.
49. Dreyer EB, Pan ZH, Storm S, Lipton SA. Greater sensitivity of larger retinal ganglion cells to NMDA-mediated cell death. Neuroreport. 1994;5:629-631.
50. Suyama K, Saito K, Chen G, Pan BS, Manji HK, Potter WZ. Alterations in cyclic AMP generation and G protein subunits following transient ischemia in gerbil hippocampus. J Cereb Blood Flow Metab. 1995;15:877-885.
51. Allen JW, Ivanova SA, Fan L, Espey MG, Basile AS, Faden AI. Group II metabotropic glutamate receptor activation attenuates traumatic neuronal injury and improves neurological recovery after traumatic brain injury. J Pharmacol Exp Ther. 1999;290:112-120.
52. Han Y, Wu SM. NMDA-evoked [Ca2+]i increase in salamander retinal ganglion cells: modulation by PKA and adrenergic receptors. Vis Neurosci. 2002;19:249-256.
53. Berrino L, Oliva P, Rossi F, Palazzo E, Nobili B, Maione S. Interaction between metabotropic and NMDA glutamate receptors in the periaqueductal grey pain modulatory system. Naunyn Schmiedebergs Arch Pharmacol. 2001;364:437-443.
54. Bruno V, Battaglia G, Copani A, et al. Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs. J Cereb Blood Flow Metab. 2001;21:1013-1033.
55. Olney JW, Labruyere J, Price MT. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science. 1989;244:1360-1362.
56. Fix AS, Horn JW, Wightman KA, et al. Neuronal vacuolization and necrosis induced by the noncompetitive N-methyl-D-aspartate (NMDA) antagonist MK(+)801 (dizocilpine maleate): a light and electron microscopic evaluation of the rat retrosplenial cortex. Exp Neurol. 1993;123:204-215.
57. Hargreaves EL, Cain DP. Hyperactivity, hyper-reactivity, and sensorimotor deficits induced by low doses of the N-methyl-D-aspartate non-competitive channel blocker MK801. Behav Brain Res. 1992;47:23-33.
58. Lipton SA. Prospects for clinically tolerated NMDA antagonists: open-channel blockers and alternative redox states of nitric oxide. Trends Neurosci. 1993;16:527-532.
59. Mawrin C, Pap T, Pallas M, Dietzmann K, Behrens-Baumann W, Vorwerk CK. Changes of retinal glutamate transporter GLT-1 mRNA levels following optic nerve damage. Mol Vis. 2003;9:10-13.
60. Vorwerk CK, Naskar R, Schuettauf F, et al. Depression of retinal glutamate transporter function leads to elevated intravitreal glutamate levels and ganglion cell death. Invest Ophthalmol Vis Sci. 2000;41:3615-3621.